<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02318134</url>
  </required_header>
  <id_info>
    <org_study_id>Nanchanguniversity</org_study_id>
    <nct_id>NCT02318134</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation for Pancreatitis</brief_title>
  <acronym>FMTP</acronym>
  <official_title>Fecal Microbiota Transplantation in SAP（Severe Acute Pancreatitis）Patients With Intestinal Barrier Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Nanchang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intestinal microbiota plays a pivotal role in the maintenance of intestinal homeostasis&#xD;
      and protecting the gut against pathogens by competing for nutrients, creating the intestinal&#xD;
      biological barrier and modulating the host immune system.After the onset of acute&#xD;
      pancreatitis,the intestinal hypoperfusion and the release of inflammatory mediators result in&#xD;
      intestinal barrier dysfunction and intestinal bacteria dysbiosis.This leads to Bacterial and&#xD;
      endotoxin translocation, which may cause infectious complications which are major causes of&#xD;
      death in SAP patients.Recently,FMT was shown its efficacy in the treatment of&#xD;
      gastrointestinal(GI) diseases and non-GI disorders associated with Intestinal flora&#xD;
      disturbance by re-establishing the damaged Intestinal Bacteria homeostasis.However,the&#xD;
      mechanism by which FMT results in cure of diseases has been poorly understood.This study aims&#xD;
      to investigate the therapeutic potential of FMT for SAP patients with intestinal barrier&#xD;
      dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators aims to restore the intestinal bacteria homeostasis through FMT by retention&#xD;
      enema with fresh bacteria,thus stabilizing intestinal barrier dysfunction,minimizing&#xD;
      bacterial translocation and preventing infectious complications.The investigators will&#xD;
      further examine the effect of FMT on inflammatory markers，the predictors of Intestinal&#xD;
      barrier injury and the incidence of infectious complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2017</start_date>
  <completion_date type="Actual">December 18, 2019</completion_date>
  <primary_completion_date type="Actual">April 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Gastrointestinal Failure Score Equal 0</measure>
    <time_frame>one week after intervention</time_frame>
    <description>The recovery of gastrointestinal dysfunction was assessed by gastrointectinal failure score. Gastrointestinal failure score is a comprehensive score for assessing gastrointestinal function. Gastrointestinal dysfunction score gets o point meaning enteral nutrition&gt; 50% of the required amount and no intra-abdominal hypertension. GIF score range from 0 to 4, and higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infectious Complications</measure>
    <time_frame>120 days</time_frame>
    <description>The incidence of any infectious complications，such as infected pancreatic necrosis, infected ascites, bacteraemia, pneumonia, urinary tract infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Organ Failure</measure>
    <time_frame>120 days</time_frame>
    <description>The incidence of organ failure,such as respiratory failure, renal failure, circulatory failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Interventions or Surgery</measure>
    <time_frame>120 days</time_frame>
    <description>number of patients who need extra interventions or surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Time and Hospital Stay</measure>
    <time_frame>6 months</time_frame>
    <description>patients' Length of Intensive care time and hospital stay due to the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>120 days</time_frame>
    <description>patients who die due to the diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diamine Oxidase（DAO）</measure>
    <time_frame>one week after intervention</time_frame>
    <description>Plasma Diamine oxidase（DAO）level as a predictor in the diagnosis of Intestinal mucosal barrier injury. The rate of decline in DAO was calculated by ((value before intervention - value one week after intervention)/ value before intervention)*100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-lactate</measure>
    <time_frame>one week after intervention</time_frame>
    <description>Plasma D-lactate level as a predictor in the diagnosis of Intestinal mucosal. The rate of decline in D-lactate was calculated by ((value before intervention - value one week after intervention)/ value before intervention)*100).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Pancreatitis</condition>
  <condition>Intestinal Bacteria Flora Disturbance</condition>
  <condition>Intestinal Dysfunction</condition>
  <condition>Fecal Microbiota Transplantation</condition>
  <arm_group>
    <arm_group_label>FMT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>FMT via a nasoduodenal tube with fresh bacteria from healthy donor</description>
    <arm_group_label>FMT group</arm_group_label>
    <other_name>Fecal Microbiota Therapy</other_name>
    <other_name>Fecal Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Normal saline via a nasoduodenal tube.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>normal saline 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of acute pancreatitis from the First Affiliated Hospital of Nanchang&#xD;
             University according to the Classification of acute pancreatitis-2012: revision of the&#xD;
             Atlanta classification and definitions by international consensus&#xD;
&#xD;
          2. Onset of pancreatitis within &lt;=2 weeks&#xD;
&#xD;
          3. complicated with gastrointestinal failure. Gastrointestinal failure was defined if the&#xD;
             patients were complicated with obvious abdominal distention, abdominal rumbling sound&#xD;
             weakening or disappearance, no self-defecation as well as intra-abdominal&#xD;
             hypertension.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. SAP complicated by Gastrointestinal bleeding or Intestinal fistula&#xD;
&#xD;
          2. Pregnancy and lactation women&#xD;
&#xD;
          3. Not signed the informed consent&#xD;
&#xD;
          4. Diabetes and autoimmune diseases&#xD;
&#xD;
          5. Multiple organ failure. Organ failure was defined as a score of 2 or more using the&#xD;
             modified Marshall scoring system including respiratory failure, renal failure and&#xD;
             circulatory.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nonghua Lv, MD</last_name>
    <role>Study Chair</role>
    <affiliation>the Frist Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.cdyfy.com/</url>
    <description>the First Affiliated Hospital of Nanchang University</description>
  </link>
  <reference>
    <citation>Liu H, Li W, Wang X, Li J, Yu W. Early gut mucosal dysfunction in patients with acute pancreatitis. Pancreas. 2008 Mar;36(2):192-6. doi: 10.1097/MPA.0b013e31815a399f.</citation>
    <PMID>18376312</PMID>
  </reference>
  <reference>
    <citation>Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25.</citation>
    <PMID>23100216</PMID>
  </reference>
  <reference>
    <citation>Reintam Blaser A, Malbrain ML, Starkopf J, Fruhwald S, Jakob SM, De Waele J, Braun JP, Poeze M, Spies C. Gastrointestinal function in intensive care patients: terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Med. 2012 Mar;38(3):384-94. doi: 10.1007/s00134-011-2459-y. Epub 2012 Feb 7.</citation>
    <PMID>22310869</PMID>
  </reference>
  <reference>
    <citation>Landy J, Al-Hassi HO, McLaughlin SD, Walker AW, Ciclitira PJ, Nicholls RJ, Clark SK, Hart AL. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther. 2011 Aug;34(4):409-15. doi: 10.1111/j.1365-2036.2011.04737.x. Epub 2011 Jun 20. Review.</citation>
    <PMID>21682755</PMID>
  </reference>
  <reference>
    <citation>Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013 Nov;145(5):946-53. doi: 10.1053/j.gastro.2013.08.058. Epub 2013 Sep 7. Review.</citation>
    <PMID>24018052</PMID>
  </reference>
  <reference>
    <citation>Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013 Aug;78(2):240-9. doi: 10.1016/j.gie.2013.03.1329. Epub 2013 May 2. Review.</citation>
    <PMID>23642791</PMID>
  </reference>
  <reference>
    <citation>Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, Young VB. Recovery of the gut microbiome following fecal microbiota transplantation. mBio. 2014 Jun 17;5(3):e00893-14. doi: 10.1128/mBio.00893-14.</citation>
    <PMID>24939885</PMID>
  </reference>
  <reference>
    <citation>Singh R, Nieuwdorp M, ten Berge IJ, Bemelman FJ, Geerlings SE. The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection. Clin Microbiol Infect. 2014 Nov;20(11):1119-25. doi: 10.1111/1469-0691.12799. Epub 2014 Nov 7. Review.</citation>
    <PMID>25274035</PMID>
  </reference>
  <reference>
    <citation>Allegretti JR, Hamilton MJ. Restoring the gut microbiome for the treatment of inflammatory bowel diseases. World J Gastroenterol. 2014 Apr 7;20(13):3468-74. doi: 10.3748/wjg.v20.i13.3468. Review.</citation>
    <PMID>24707129</PMID>
  </reference>
  <reference>
    <citation>Shankar V, Hamilton MJ, Khoruts A, Kilburn A, Unno T, Paliy O, Sadowsky MJ. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome. 2014 Apr 21;2:13. doi: 10.1186/2049-2618-2-13. eCollection 2014.</citation>
    <PMID>24855561</PMID>
  </reference>
  <reference>
    <citation>Cui LH, Wang XH, Peng LH, Yu L, Yang YS. [The effects of early enteral nutrition with addition of probiotics on the prognosis of patients suffering from severe acute pancreatitis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2013 Apr;25(4):224-8. doi: 10.3760/cma.j.issn.2095-4352.2013.04.011. Chinese.</citation>
    <PMID>23660099</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 12, 2014</study_first_submitted>
  <study_first_submitted_qc>December 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2014</study_first_posted>
  <results_first_submitted>February 23, 2021</results_first_submitted>
  <results_first_submitted_qc>March 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2021</results_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Nanchang University</investigator_affiliation>
    <investigator_full_name>Lingyu Luo</investigator_full_name>
    <investigator_title>Physician-in-charge</investigator_title>
  </responsible_party>
  <keyword>Severe acute pancreatitis</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Intestinal barrier dysfunction</keyword>
  <keyword>Intestinal flora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT02318134/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between November 2017 and April 2019 from the intensive unit care, Department of Gastroenterology, First Affiliated Hospital of Nanchang University.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FMT Group</title>
          <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FMT Group</title>
          <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="12.4"/>
                    <measurement group_id="B2" value="49.9" spread="13.7"/>
                    <measurement group_id="B3" value="48.6" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body mass index</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="3.7"/>
                    <measurement group_id="B2" value="25.6" spread="4.2"/>
                    <measurement group_id="B3" value="26.0" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Causes of pancreatitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Biliary</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Alcohol</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hypertriglyceridemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Iintra-abdominal pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.7" spread="2.4"/>
                    <measurement group_id="B2" value="14.5" spread="2.5"/>
                    <measurement group_id="B3" value="14.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from first symptoms to admission</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="B2" value="3" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="B3" value="3" lower_limit="1" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from admission to intervention</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="B2" value="1.5" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="B3" value="2" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Gastrointestinal Failure Score Equal 0</title>
        <description>The recovery of gastrointestinal dysfunction was assessed by gastrointectinal failure score. Gastrointestinal failure score is a comprehensive score for assessing gastrointestinal function. Gastrointestinal dysfunction score gets o point meaning enteral nutrition&gt; 50% of the required amount and no intra-abdominal hypertension. GIF score range from 0 to 4, and higher scores mean a worse outcome.</description>
        <time_frame>one week after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FMT Group</title>
            <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gastrointestinal Failure Score Equal 0</title>
          <description>The recovery of gastrointestinal dysfunction was assessed by gastrointectinal failure score. Gastrointestinal failure score is a comprehensive score for assessing gastrointestinal function. Gastrointestinal dysfunction score gets o point meaning enteral nutrition&gt; 50% of the required amount and no intra-abdominal hypertension. GIF score range from 0 to 4, and higher scores mean a worse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infectious Complications</title>
        <description>The incidence of any infectious complications，such as infected pancreatic necrosis, infected ascites, bacteraemia, pneumonia, urinary tract infection.</description>
        <time_frame>120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FMT Group</title>
            <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infectious Complications</title>
          <description>The incidence of any infectious complications，such as infected pancreatic necrosis, infected ascites, bacteraemia, pneumonia, urinary tract infection.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any infectious complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented IPN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suspected or documented IPN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>infected ascites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bacteremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Organ Failure</title>
        <description>The incidence of organ failure,such as respiratory failure, renal failure, circulatory failure.</description>
        <time_frame>120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FMT Group</title>
            <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Organ Failure</title>
          <description>The incidence of organ failure,such as respiratory failure, renal failure, circulatory failure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any persistent organ failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent respiratory failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent renal failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent circulatory failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Interventions or Surgery</title>
        <description>number of patients who need extra interventions or surgery</description>
        <time_frame>120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FMT Group</title>
            <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Interventions or Surgery</title>
          <description>number of patients who need extra interventions or surgery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percutaneous or endoscopic transmural drainage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percutaneous or endoscopic transmural necrosectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Open surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mechanical ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal replacement therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Time and Hospital Stay</title>
        <description>patients' Length of Intensive care time and hospital stay due to the disease</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FMT Group</title>
            <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intensive Care Time and Hospital Stay</title>
          <description>patients' Length of Intensive care time and hospital stay due to the disease</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Intensive care stay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="3" upper_limit="103"/>
                    <measurement group_id="O2" value="11" lower_limit="2" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital stay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="9" upper_limit="122"/>
                    <measurement group_id="O2" value="23" lower_limit="5" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>patients who die due to the diseases</description>
        <time_frame>120 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FMT Group</title>
            <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>patients who die due to the diseases</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diamine Oxidase（DAO）</title>
        <description>Plasma Diamine oxidase（DAO）level as a predictor in the diagnosis of Intestinal mucosal barrier injury. The rate of decline in DAO was calculated by ((value before intervention - value one week after intervention)/ value before intervention)*100)</description>
        <time_frame>one week after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FMT Group</title>
            <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
          </group>
        </group_list>
        <measure>
          <title>Diamine Oxidase（DAO）</title>
          <description>Plasma Diamine oxidase（DAO）level as a predictor in the diagnosis of Intestinal mucosal barrier injury. The rate of decline in DAO was calculated by ((value before intervention - value one week after intervention)/ value before intervention)*100)</description>
          <units>percent change of DAO</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" lower_limit="-46.2" upper_limit="0.57"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-4.32" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D-lactate</title>
        <description>Plasma D-lactate level as a predictor in the diagnosis of Intestinal mucosal. The rate of decline in D-lactate was calculated by ((value before intervention - value one week after intervention)/ value before intervention)*100).</description>
        <time_frame>one week after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.&#xD;
normal saline: Normal saline via a nasoduodenal tube.</description>
          </group>
          <group group_id="O2">
            <title>FMT Group</title>
            <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.&#xD;
Fecal Microbiota Transplantation: FMT via a nasoduodenal tube with fresh bacteria from healthy donor</description>
          </group>
        </group_list>
        <measure>
          <title>D-lactate</title>
          <description>Plasma D-lactate level as a predictor in the diagnosis of Intestinal mucosal. The rate of decline in D-lactate was calculated by ((value before intervention - value one week after intervention)/ value before intervention)*100).</description>
          <units>percent change of D-lactate</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="-1.06" upper_limit="0.85"/>
                    <measurement group_id="O2" value="-0.28" lower_limit="-3.72" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FMT Group</title>
          <description>In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent circulatory failure</sub_title>
                <description>Systolic blood pressure below 90 mm Hg, not fluid responsive or pH below 7.3</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>intra-abdominal bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infected pancreatic necrosis</sub_title>
                <description>Positive culture of peripancreatic fluid or pancreatic necrosis obtained by either fine-needle aspiration or during the first percutaneous or endoscopic drainage</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent renal failure</sub_title>
                <description>Serum Creatinine over 170 μmol/l or 1.9 mg/dl</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent respiratory failure</sub_title>
                <description>PaO2/FiO2 below 300</description>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="30"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bloating</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="30"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infected ascites</sub_title>
                <description>bacteria or fungi detected in aspirate of intraperitoneal fluid</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <description>positive blood culture</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>Positive sputum or endotracheal culture</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Positive urine culture</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ling Ding</name_or_title>
      <organization>First Affiliated Hospital of Nanchang University</organization>
      <phone>15279196058</phone>
      <email>2495802456@qq.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

